Table 1.

Demographic and clinical characteristics of schizophrenia patients and healthy controls

	Schizophrenia patients	Healthy controls	Two‐sided
	(n = 21)	(n = 28)	P‐value
Age	34.1 ± 6.7a	31.5 ± 7.2a	0.20b
Gender	5 F–16 M	8 F–20 M	0.71c
Years of education	14.2 ± 3.2a	16.7 ± 3.0a	0.01b
Verbal intelligence (IQ in WST test)	105.2 ± 8.8a	107.4 ± 6.8a	<0.001b
Attention span (TN‐E in d2 test)	152.0 ± 34.0a	183.3 ± 43.3a	<0.001b
PDI
Yes/no	17.2 ± 7.8a	5.8 ± 5.6a	<0.001b
Conviction	54.8 ± 33.4a	15.0 ± 15.7a	<0.001b
Distress	55.1 ± 32.4a	10.9 ± 12.6a	<0.001b
Preoccupation	51.3 ± 30.0a	11.5 ± 12.9a	<0.001b
Sum	178.4 ± 100.8a	43.1 ± 45.4a	<0.001b
PANNS
Positive	14.1 ± 4.8a	–	–
Negative	13.6 ± 5.4a	–	–
General	27.3 ± 9.4a	–	–
Medication
Daily olanzapine equivalent dose (mg)	10.9 ± 5.2	–	–

^aMean ± SD.

^bTwo‐sample t‐test.

^cChi‐squared test.